Provided by Tiger Trade Technology Pte. Ltd.

ProQR Therapeutics NV

2.36
+0.13005.83%
Post-market: 2.360.00000.00%18:45 EST
Volume:1.07M
Turnover:2.38M
Market Cap:248.61M
PE:-4.89
High:2.38
Open:2.23
Low:2.15
Close:2.23
52wk High:3.46
52wk Low:1.07
Shares:105.35M
Float Shares:67.53M
Volume Ratio:1.19
T/O Rate:1.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4823
EPS(LYR):-0.3339
ROE:-103.76%
ROA:-24.02%
PB:3.71
PE(LYR):-7.07

Loading ...

ProQR Therapeutics to Participate in Evercore Healthcare Conference

Reuters
·
Dec 01

ProQR Therapeutics N.V.'s (NASDAQ:PRQR) 29% Share Price Plunge Could Signal Some Risk

Simply Wall St.
·
Nov 24

ProQR Therapeutics Q3 EPS EUR -0.1

Reuters
·
Nov 20

ProQR Q3 revenue misses estimates, reports net loss

Reuters
·
Nov 06

BRIEF-ProQR Therapeutics Q3 EPS EUR -0.1

Reuters
·
Nov 06

ProQR Therapeutics Q3 Revenue EUR 2.882 Million VS. Ibes Estimate EUR 4.37 Million

THOMSON REUTERS
·
Nov 06

ProQR Therapeutics NV expected to post a loss of 10 cents a share - Earnings Preview

Reuters
·
Oct 31

ProQR Therapeutics NV held annual shareholder meeting

Reuters
·
Oct 24

ProQR Therapeutics Receives CTA Authorization for Phase 1 Trial of AX-0810 in Europe

Reuters
·
Oct 20

ProQR Therapeutics Nv - Receives Cta Authorization for Phase 1 Study of Ax-0810

THOMSON REUTERS
·
Oct 20

ProQR Therapeutics NV to Participate in Chardan's Annual Genetic Medicines Conference

Reuters
·
Oct 13

ProQR Therapeutics N.V.'s (NASDAQ:PRQR) Price Is Out Of Tune With Revenues

Simply Wall St.
·
Oct 10

ProQR Therapeutics NV reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 08

ProQR Q2 revenue and EPS miss estimates

Reuters
·
Aug 07

ProQR Therapeutics NV expected to post a loss of 8 cents a share - Earnings Preview

Reuters
·
Aug 01

ProQR Therapeutics NV Submits CTA for AX-0810 to Target Cholestatic Diseases, Showcasing Progress in CNS Applications at Upcoming RNA Editing Summit

Reuters
·
Jul 28

BRIEF-ProQR Announces CTA Submission For Phase 1 Study Of AX-0810 Targeting NTCP

Reuters
·
Jun 27

ProQR Seeks EU Approval for Liver Cell Protein Trial

MT Newswires Live
·
Jun 27

ProQR Therapeutics NV Submits Clinical Trial Application for First Human Study of AX-0810 Targeting NTCP, Marking Milestone in Axiomer™ RNA Editing Platform Development

Reuters
·
Jun 27